TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32153038
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Occlusal Splint and Counselling (OSCS)
Study: 32813887
Drug: GRAZAX® (sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRAZAX® (sublingual immunotherapy) for 2 years
Study: 35084724
Drug: Salbutamol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol plus budesonide nebulizer (budesonide 0.5 mg nebulized three times for 20 minutes)
Study: 32332464
Drug: Active placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo, midazolam 0.045 mg/kg
Study: 34031723
Drug: Dual autonomic
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual autonomic blockade (DAB) with 0.04 mg/kg atropine and 0.2 mg/kg metoprolol
Study: 36449873
Drug: Macrophage-activating gel
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrophage-activating gel
Study: 33045675
Drug: Chromium picolinate
Normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chromium picolinate (400 mcg/day)
Study: 33357708
Drug: APS pretreatment
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APS pretreatment (0.6 g/L)
Study: 35983959
Drug: Active THC
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active THC cigarette (26.25 mg/2.7% THC)
Study: 33242457
Drug: Nevirapine treatment
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine treatment
Study: 35351134
Drug: Biocan DHPPi+L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biocan DHPPi+L (Bioveta, Czech)
Study: 33683065
Drug: Interferon gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon gamma (IFN‐γ) 500,000 IU administered subcutaneously, daily for 5 days
Study: 33683065
Drug: Complex therapy
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex therapy of the disease (control group not explicitly mentioned)
Study: 35810063
Drug: Quadrivalent subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent subunit influenza vaccine (single dose, with a boosting dose at day 28 for children aged 3–8 years)
Study: 35810063
Drug: Split‐virion influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split‐virion influenza vaccine (control group)
Study: 35734824
Drug: Precision-medicine approach
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precision-medicine approach (comprehensive diagnostic workup and pharmacological treatment specific for the underlying cause)
Study: 35734824
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (routine diagnostic workup and standard medical treatment for acute coronary syndrome)
Study: 35734824
Drug: Precision-medicine approach
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precision-medicine approach
Study: 33802219
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement (DS) containing Octacosanol (20 mg) and vitamin K2 (45 µg)
Study: 35253599
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (forward bending, walking, and medication)
Study: 35367876
Drug: Naming treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naming treatment (modified semantic feature analysis)
Study: 35367876
Drug: Non-naming treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-naming treatment (auditory comprehension, copying text, and reading)
Study: 34228613
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA) 15 mg/kg in 100 ml saline solution administered 20 minutes before the end of surgery
Study: 34228613
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 100 ml saline solution without TXA
Study: 33160931
Drug: Skin patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin patch test (SPT) with sodium lauryl sulfate, cocamidopropyl betaine, propylene glycol, aluminum chloride hexahydrate, menthol, triclosan, and titanium dioxide
Study: 33160931
Drug: Skin patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin patch test (SPT)
Study: 33046478
Drug: Multidisciplinary team‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary team‐based medication optimisation
Study: 33879219
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) - medical consultation alone
Study: 34083331
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy with corresponding targeted drugs for patients with actionable alterations.
Study: 34083331
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor treatment with sintilimab for patients without actionable alterations.
Study: 34083331
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with sintilimab or atezolizumab after resistance to vemurafenib, niraparib, and palbociclib.
Study: 34083331
Drug: Single-agent immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent immunotherapy (sintilimab) in the single-agent immunotherapy group.
Study: 33449867
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of r-IPL and fractional CO2 laser
Study: 33449867
Drug: Therapeutic standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic standard dose of the fractional CO2 laser
Study: 35291025
Drug: Individualised STOPP/START-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised STOPP/START-based medication optimisation recommendations discussed with patients and physicians
Study: 35291025
Drug: Individualised STOPP/START-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised STOPP/START-based medication optimisation recommendations
Study: 32914161
Drug: Dexmedetomidine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.2 μg/kg
Study: 32914161
Drug: Fentanyl 0.2
Normalized name: fentanyl 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.2 μg/kg
Study: 32914161
Drug: Control (Bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Bupivacaine 0.5% 2 mL)
Study: 36215947
Drug: Trivalent ganglioside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821
Study: 35414106
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg (control group)
Study: 32798261
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg saffron daily for 12 weeks
Study: 34051389
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of HPV vaccine
Study: 35279213
Drug: Rusk-like biscuit
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rusk-like biscuit powder with hen's egg (HE), cow’s milk (CM), peanut (PN), and hazelnut (HN) (initially approximately 2 mg of each food protein) for 6–8 months.
Study: 35279213
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group receiving rusk-like biscuit powder without HE, CM, PN, and HN on a daily basis.
Study: 32438452
Drug: Eliglustat therapy
Normalized name: Eliglustat
DrugBank: Eliglustat (DB09039)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eliglustat therapy
Study: 33639045
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (100 mcg menaquinone-7) and vitamin D3 (10 mcg calcitriol)
Study: 36190994
Drug: Dexamethasone 20
Normalized name: dexamethasone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 20 mg daily
Study: 32909921
Drug: CPAP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP + OA (oral airway open)
Study: 32909921
Drug: CPAP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP + OA (oral airway closed)
Study: 32909921
Drug: CPAP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP + OA (oral airway open) and CPAP + OA (oral airway closed)
Study: 39179982
Drug: Solution-Focused Brief
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution-Focused Brief Therapy (SFBT)
Study: 32227713
Drug: Yun's optimized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yun's optimized pelvic floor training (OPFT) therapy for 6 weeks followed by 6 weeks of traditional pelvic floor muscle exercises (PFME)
Study: 32227713
Drug: Traditional pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional pelvic floor muscle exercises (PFME) for 6 weeks followed by 6 weeks of Yun's OPFT therapy
Study: 35026375
Drug: Favipiravir 1800
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Favipiravir 1800 mg by mouth twice daily on day 1 followed by 800 mg twice daily for 5 to 7 days
Study: 32250328
Drug: Conventional neurodevelopmental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional neurodevelopmental treatment (NDT)
Study: 35342931
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment + aprotinin
Study: 34514764
Drug: Combination program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination program including smartphone nutrition education, physical activity (aerobics exercise for 45 minutes three times per week), and cognitive behavioral therapy (CBT) sessions (8 sessions designed for children)
Study: 32300382
Drug: Chemical blockage
Normalized name: Blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical blockage of celiac ganglions by ethanol injection
Study: 35050348
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent nivolumab
Study: 35050348
Drug: Combination nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination nivolumab and ipilimumab
Study: 32676853
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for GI malignancy
Study: 32676853
Drug: Pre-chemotherapy screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-chemotherapy screening
Study: 32676853
Drug: Investigations for
Normalized name: INVESTIGATIONAL DRUGS FOR CONSTIPATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigations for chemotherapy-induced symptoms
Study: 36428060
Drug: Online laughter
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online laughter therapy (twice weekly for four weeks)
Study: 33715056
Drug: Cement applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cement applied on implant surfaces (group 2)
Study: 33715056
Drug: Cement applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cement applied on both bone and implant surfaces (group 3)
Study: 35812412
Drug: WIBP-CorV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WIBP-CorV vaccine (2.5, 5.0, and 10.0μg/dose)
Study: 35812412
Drug: WIBP-CorV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WIBP-CorV vaccine
Study: 33433260
Drug: Usual occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual occupational therapy exercises (Control)
Study: 32998926
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg subcutaneous weekly until week 4, then at week 8; escalated to 300 mg subcutaneous every 4 weeks for non-responders at week 12; switched to adalimumab biosimilar 40 mg subcutaneous every 2 weeks for non-responders at week 24.
Study: 32998926
Drug: Standard-of-care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care treatment at the discretion of the physician.
Study: 32826001
Drug: Breathing retraining
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breathing retraining and four weekly manual therapy sessions (immediate start)
Study: 32826001
Drug: Breathing retraining
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breathing retraining and four weekly manual therapy sessions (delayed start)
Study: 34981467
Drug: Curcuminoids (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids (500 mg/day)
Study: 35331684
Drug: Nitroglycerin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (500 μg)
Study: 33472541
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment effect estimation methods
Study: 35982457
Drug: Dental Care
Normalized name: Arm And Hammer Dental Care Mint Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental Care Professionals (dental therapists and dental nurses) visiting care homes every 6 months and monthly for the first 3 months, then three-monthly thereafter
Study: 33896224
Drug: Somatropin treatment
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Somatropin treatment
Study: 35984704
Drug: CT900 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT900 at a dose of 12 mg/m2 every 2 weeks (q2Wk)
Study: 34281849
Drug: Low-dose OSK-0028
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose OSK-0028 (0.25 μg/kg/h)
Study: 34281849
Drug: High-dose OSK-0028
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose OSK-0028 (0.5 μg/kg/h)
Study: 34281849
Drug: OSK-0028 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSK-0028 (both doses)
Study: 36011519
Drug: Telemedicine‐delivered counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine‐delivered counseling and printed materials on diet and medication adherence
Study: 34332557
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg/day monotherapy
Study: 34332557
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with allogeneic CD8 + CD56+ NKT cell infusions twice per month for 12 cycles
Study: 32228462
Drug: Couple-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couple-based intervention arm (patients and spouses receive four-weekly structured group education & training sessions and 2 months of weekly tailored behavior change boosters)
Study: 35906331
Drug: Higher-density formula
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-density formula (HDF, 90 kcal/100 ml)
Study: 35906331
Drug: Standard-density formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-density formula (SDF, 67 kcal/100 ml)
Study: 32672570
Drug: Pericardium patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pericardium patch grafts
Study: 32268801
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus exercise
Study: 36090717
Drug: Tropocollagen gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropocollagen gel applied to the skin around the wound
Study: 36170500
Drug: Bionic pancreas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bionic pancreas treatment with insulin aspart or insulin lispro
Study: 36170500
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (any insulin-delivery method with unblinded, real-time continuous glucose monitoring)
Study: 32401385
Drug: Dexlansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexlansoprazole 60 mg, once daily before breakfast for 8 weeks
Study: 32401385
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg, once daily before breakfast for 8 weeks
Study: 33055188
Drug: High-dose eplerenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose eplerenone
Study: 32921501
Drug: High-dose pitavastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pitavastatin (4 mg/d)
Study: 34121344
Drug: High-dose biologics
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose biologics
Study: 34642026
Drug: CP/ganitumab (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP/ganitumab (18 mg/kg q3w)
Study: 33278625
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin (12 mg once daily for 5 days)
Study: 33278625
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin + doxycycline (12 mg ivermectin single dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days)
Study: 34602110
Drug: Fluoxetine or
Normalized name: fluoxetine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine or Sertraline treatment for 6 weeks
Study: 34602110
Drug: SSRIs (Fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (Fluoxetine or Sertraline)
Study: 35699705
Drug: Varenicline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (1 mg twice daily; n = 300)
Study: 33032795
Drug: Self-regulation programme
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-regulation programme (4-week duration, including one 20-30 min face-to-face education session and 15-20 min telephone follow-ups twice per week)
Study: 33787192
Drug: Zingiber officinale
Normalized name: Zingiber officinale oil
DrugBank: Ginger oil (DB14690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zingiber officinale (Tablet Vomigone 500 mg II tds) and Echinacea (Tablet Rucoldup I tds) for seven days in addition to standard treatment (Hydroxychloroquine)
Study: 33787192
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (Hydroxychloroquine)
Study: 34378863
Drug: High-dose ergocalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ergocalciferol (double dosage from K/DOQI guidelines) for 8 weeks
Study: 34378863
Drug: Conventional-dose ergocalciferol
Normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional-dose ergocalciferol (standard dosage according to K/DOQI guidelines) for 8 weeks
Study: 34378863
Drug: High-dose ergocalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ergocalciferol (for subgroup with serum 25[OH]D <20 ng/ml)
Study: 34378863
Drug: Conventional-dose ergocalciferol
Normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional-dose ergocalciferol (for subgroup with serum 25[OH]D <20 ng/ml)
Study: 32450709
Drug: X-ray irradiation
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: X-ray irradiation of nitroxyl radical solutions
Study: 34996424
Drug: Internet-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioral therapy (ICBT) for two menstrual cycles
Study: 36403542
Drug: Cream with
Normalized name: CREAM WITH APPLICATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream with nanoparticles containing vitamin E
Study: 36403542
Drug: Cream without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cream without nanoparticles or vitamin E (Control 1)
Study: 36403542
Drug: Cream with
Normalized name: CREAM WITH APPLICATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream with nanoparticles without vitamin E (Control 2)
Study: 35028688
Drug: Vaccinium fruit
Normalized name: Vaccinium myrtillus fruit
DrugBank: Bilberry (DB14235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinium fruit supplements
Study: 36460535
Drug: FD MVA-BN
Normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FD MVA-BN vaccine (3 lots)
Study: 33650407
Drug: Aviron Rapid®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aviron Rapid® + standard symptomatic therapy
Study: 33650407
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + standard symptomatic therapy
Study: 34426507
Drug: Plasma adiponectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma adiponectin levels of 19.2 μg/mL (3rd quartile)
Study: 34426507
Drug: Plasma adiponectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma adiponectin levels of 13.9 μg/mL (2nd quartile)
Study: 34426507
Drug: Plasma adiponectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma adiponectin levels of 9.2 μg/mL (1st quartile)
Study: 34426507
Drug: 1 μg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg/mL lower plasma adiponectin
Study: 32580987
Drug: Intrapartum antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapartum antibiotics
Study: 32932482
Drug: Randomization of
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization of pixel positions in hologram display using a liquid crystal modulator
Study: 33998882
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) chewing gum (50 mg)
Study: 38092285
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing plus cognitive behavioral therapy
Study: 35420695
Drug: Stereotactic adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic adjuvant pelvic radiation to a dose of 30 Gy in 5 fractions administered every other day or once weekly